About: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 1994 (uk) article scientifique publié en 1994 (fr) im Oktober 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 1994 (ast) scientific article published on 01 October 1994 (en)
publication date	wds:Q58481515-75731FED-D441-4031-982C-1C1BD6337214
publication date	1994-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58481515-A9EFF9A9-7F53-416F-9150-23E1703DD968
language of work or name	English
author name string	wds:Q58481515-1D568E19-1B74-4648-A85D-ACC8E60998A4 wds:Q58481515-1E64754C-03AC-4FB1-9734-27D27A613030 wds:Q58481515-30387468-C3CF-4009-ACD4-7429161C26C7 wds:Q58481515-57AD3B52-9E10-40C6-B3A7-29FB82834EE5 wds:Q58481515-6D9CE4BA-75AC-421E-B84E-5C0E35483B00 wds:Q58481515-79F5C884-9B21-4390-8808-7666E98F4EB4 wds:Q58481515-90CE2555-D062-400E-BAA6-CBBF9CDD381D wds:Q58481515-B85D6C32-CEE6-4C5F-96BD-FB443CAA519E wds:Q58481515-FCE8D19A-16D3-44A3-9824-827F095CC57B
author name string	G Murphy R J Gould J Vermylen J S Barrett K Peerlinck J Arnout I De Lepeleire D Panebianco E Hand
rdfs:label	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (en) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (nl)
skos:prefLabel	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (en) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (nl)
name	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (en) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (nl)
author	wds:Q58481515-2D7687FE-6E23-40C7-8053-B018C24C39E3
author	Hans Deckmyn
title	wds:Q58481515-1CE309FD-E9DD-4024-864F-043205D4E6F9
title	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men (en)
page(s)	wds:Q58481515-691D1216-80AE-4193-94F5-B551025B6879
page(s)	377-388
instance of	wds:Q58481515-CD83C189-BFB6-4B97-9A6C-263CE8B37DD2
instance of	scholarly article
main subject	wds:Q58481515-21C3BD38-4788-46A6-8B53-B0BE4E16EFB4
main subject	pharmacokinetics
PubMed ID	wds:Q58481515-E1CBAC1C-9E75-40F6-906C-B034B9EE659C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7955799
PubMed ID	7955799
published in	wds:Q58481515-9359655B-47A8-451F-995A-5226025F74FB
published in	Clinical Pharmacology & Therapeutics
issue	wds:Q58481515-F8CDE528-1B38-4531-818B-F775C47D12A4
volume	wds:Q58481515-2F5609E7-81D7-4903-8F5A-163E45192D4F
issue	4
volume	56
DOI	wds:Q58481515-00BE8DA5-B391-4BE5-BE54-C6BA66ABF4A9
DOI	http://dx.doi.org/10.1038/CLPT.1994.152
DOI	10.1038/CLPT.1994.152
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58481515
is cites work of	Platelets: is aspirin sufficient or must we know how to pronounce abciximab? Tirofiban. A review of its use in acute coronary syndromes Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects Bioactive Mimetics of Conotoxins and other Venom Peptides The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations Translating from the rivers of Babylon to the coronary bloodstream Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics Historical perspective and future directions in platelet research Role of platelets in restenosis after percutaneous coronary revascularization Integrin αIIbβ3: from discovery to efficacious therapeutic target Privileged frameworks from snake venom. Antiplatelet medications and evolving antithrombotic medication Augmentation of in-vitro clot dissolution by low frequency high-intensity ultrasound combined with antiplatelet and antithrombotic drugs Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study Antiplatelet therapy for treatment of acute coronary syndromes Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model Antithrombotic therapies in primary angioplasty: rationale, results and future directions Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes] Fibrinogen receptor antagonists: design and clinical applications Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics Applications of anti-platelet monitoring in catheterization laboratory Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943 Monitoring antiplatelet therapy: What is the best method? Substituted coumarins as esterase-sensitive prodrug moieties with improved release rates Two new improved approaches to the synthesis of coumarin-based prodrugs From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs. A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies The platelet: life on the razor's edge between hemorrhage and thrombosis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software